Biofluidica Announces $6 Million Series B2 Funding To Support The Commercialization Of Its Liquid Biopsy Microfluidics Platform, The Liquidscan™, And The Development Of Its Advanced Handheld Covid-19 Detection Device For Consumer At-Home Testing
Biofluidica Announces $6 Million Series B2 Funding To Support The Commercialization Of Its Liquid Biopsy Microfluidics Platform, The Liquidscan™, And The Development Of Its Advanced Handheld Covid-19 Detection Device For Consumer At-Home Testing
02/08/22, 6:47 PM
Location
san diegoMoney raised
$6 million
Round Type
series b
BioFluidica, Inc., a biotechnology company developing a diagnostic platform allowing for disease management and diagnosis, today announced that it has raised over $6 million in the initial closings of its Series B2 financing. Additional closings in this targeted $10 million financing are anticipated following successful completion of development milestones relating to BioFluidica's handheld infectious disease detection device using nanofluidics for ultrafast high-sensitivity detection of virus particles. The funding round was led by BioFluidica's existing investor base, with participation from new investors.
Company Info
Location
san diego, california, united states
Additional Info
BioFluidica is a privately held biotechnology company that has developed a revolutionary liquid biopsy platform allowing for isolation and analysis of all liquid biopsy biomarkers including cells, exosomes and cfDNA on one fully automated platform. The Biofluidica platform has been clinically validated on 9 different cancer and prenatal patient samples and is currently used for a large variety of research applications to advance the field of liquid biopsy. The ultralow sensitivity expands the capability of current liquid biopsy applications. For more information, please visit www.biofluidica.com